Alphabet Inc Class A vs Heron Therapeutics Inc — how do they compare? Alphabet Inc Class A trades at $355.7 (market cap $4.52T), while Heron Therapeutics Inc trades at $0.48 (market cap $84.50M). The key difference: Alphabet Inc Class A is far larger — about 53491.1× Heron Therapeutics Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GOOGL | HRTX | |
|---|---|---|
Market Cap | $4.52T | $84.50M |
Sector | Media | Health |
52-Week High | $402.62 | $2.02 |
52-Week Low | $182.97 | $0.39 |
Enterprise Value | $4.49T | $182.40M |
Dividend Yield | 0.24% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $356.14, down 0.94% on the day, with strong technical support at $355 and resistance at $375. The stock shows bullish momentum in moving averages while oscillators remain neutral. Recent earnings consistently beat expectations, with Q1 2026 EPS of $5.11 significantly exceeding the $2.64 forecast. Revenue growth accelerated to $402.84 billion in 2025, with net income margins expanding to 32.8%.
Alphabet presents a compelling investment case with 85% analyst buy ratings and a $431.78 consensus price target representing 21% upside. Strong AI integration, YouTube price increases, and cloud partnerships drive growth, though regulatory scrutiny and tech sector volatility remain key risks. The company's robust cash flow generation and strategic investments position it well for sustained outperformance.
Heron Therapeutics (HRTX) trades at $0.49, up 13.93% today, showing volatile momentum amid mixed technical signals. The company maintains strong gross margins of 71.12% but struggles with profitability, posting a net loss of $20.20 million in 2025. Recent Q1 2026 earnings missed expectations with a $0.04 loss per share, though management reaffirmed full-year guidance. Analyst consensus remains overwhelmingly bullish with 94.74% buy ratings, contrasting with a recent Zacks Strong Sell designation.
HRTX presents a high-risk opportunity with significant analyst support but persistent financial challenges. The bullish sentiment stems from potential patent developments and commercial execution, while risks include ongoing losses, competitive pressures, and the discrepancy between analyst optimism and recent negative ratings. The stock's current valuation at 0.49x sales appears reasonable if the company can achieve profitability.
Trailing returns across standard periods
Latest headlines on both assets
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →